PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

We explore recent biorobotics developments, including biohybrid lobster bots and a nature-inspired artificial eye, that will ...

PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027.

PROCEPT BioRobotics (NASDAQ:PRCT) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

View PROCEPT BioRobotics Corp. PRCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...

Wells Fargo resumed coverage of Procept BioRobotics (PRCT) with an Overweight rating and $112 price target The firm believes aquablation remains early stages in its adoption, which will be further ...

Taking a look inside the human body has never been easier — just swallow a camera in the shape of a pill. However, what is not quite as easy is retrieving a piece of whatever you’re viewing. This is ...